Collaborations Help Alkermes Flip to Profitability

Alkermes (NASDAQ:ALKS), a commercial-stage drug manufacturer specializing in diseases of the central nervous system, reported its second-quarter results on Thursday. A large collaboration payment from its partnership with Biogen (NASDAQ:BIIB) helped drive total revenue growth of 39%. The boost allowed the company to swing into the black on the bottom line.